Bicara Therapeutics (BCAX) Total Non-Current Liabilities (2023 - 2024)
Bicara Therapeutics (BCAX) reported Total Non-Current Liabilities of $18.1 million for Q4 2024, up 17.23% on a YoY basis from $15.5 million in Q1 2024, and up 23.96% quarter-over-quarter from $14.6 million in Q3 2024.
Bicara Therapeutics (BCAX) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends
Bicara Therapeutics has reported Total Non-Current Liabilities for 2 years, with the latest figure at $18.1 million in Q4 2024.
- For the quarter ending Q4 2024, Total Non-Current Liabilities rose 17.23% year-over-year to $18.1 million; the trailing twelve-month figure through Dec 2024 stood at $18.1 million (up 17.23% YoY), and the FY2024 full-year result was $18.1 million, up 17.23% from the prior year.
- Total Non-Current Liabilities for Q4 2024 stood at $18.1 million, up from $14.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $18.1 million in Q4 2024, with the low at $14.6 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Bicara Therapeutics | 1.41 Bn | 1.41 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 18.12 Mn |
| Sep 30, 2024 | 14.62 Mn |
| Dec 31, 2023 | 15.46 Mn |